Macrogenics Inc
MGNX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.25
KIRA · Stoqly’s AI analyst, in plain words
- Macrogenics Inc had $150M of revenue in fiscal 2025, down 0.3% on the year before. Over five years, revenue changed +7.3% a year on average.
- Its operating margin was −48.7%, up 25.0 pts: of every 100 in sales, about −49 is left after running the business.
- Macrogenics Inc lost $74.6M in fiscal 2025.
- Free cash flow was −$83.0M in fiscal 2025, −55.5% of revenue.
Market cap
$143M
P/E
—
Revenue
$150M
Net income
−$74.6M
Free cash flow
−$83.0M
Operating margin
−48.7%
Macrogenics Inc in 30 seconds · fiscal 2025
Are sales growing?
−0.3%
No. Sales fell 0.3% last year.
Does it make a profit?
−49.9%
No. It lost money last year.
Does profit turn into cash?
−55.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Macrogenics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- MACROGENICS INC
- CIK
- 0001125345
Macrogenics Inc · MGNX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $77.4M | $152M | $58.7M | $150M | $150M |
| Revenue growth | −26.2% | 96.2% | −61.3% | 155.3% | −0.3% |
| Gross margin | 96.6% | 97.8% | 98.9% | 99.4% | 100.0% |
| Operating margin | −261.9% | −79.9% | −286.4% | −73.7% | −48.7% |
| Net income | −$202M | −$120M | −$9.1M | −$67.0M | −$74.6M |
| Net margin | −261.0% | −78.8% | −15.4% | −44.7% | −49.9% |
| Diluted EPS | −$3.37 | −$1.95 | −$0.15 | −$1.07 | −$1.18 |
| Cash | |||||
| Cash from operations | −$144M | −$87.0M | −$78.2M | −$68.4M | −$81.0M |
| Capital expenditure | $6.2M | $3.6M | $1.8M | $3.7M | $1.9M |
| Free cash flow | −$150M | −$90.6M | −$80.0M | −$72.1M | −$83.0M |
| FCF margin | −193.7% | −59.6% | −136.1% | −48.1% | −55.5% |
| Share count change | 14.3% | 2.5% | 0.8% | 1.1% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $123M | $109M | $101M | $183M | $57.2M |
| Shareholders' equity | $240M | $142M | $153M | $116M | $55.6M |
| Current ratio | 3.7x | 4.6x | 4.5x | 3.9x | 5.1x |
| Interest coverage | — | — | −117.7x | −99.2x | −8.6x |
| Returns and quality | |||||
| Return on equity | −75.5% | −62.8% | −6.1% | −49.9% | −86.9% |
| Return on tangible equity | −84.3% | −84.3% | −5.9% | −57.7% | −134.2% |
| Piotroski F-score | 1 | 5 | 2 | 2 | 3 |
| Altman Z'' | −6.9 | −10.5 | −10.4 | −12.5 | −12.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Macrogenics Inc · MGNX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.25 a share, the company is worth $143M.
Source: SEC EDGAR XBRL filings (CIK 0001125345). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.